Live
FierceBiotechRare disease advocates stage 'funeral' at FDA, demand 4 actions of agency and CongressCellMitochondrial control of glycerolipid synthesis by a PEP shuttleCellFunctional RNA splitting drove the evolutionary emergence of type V CRISPR-Cas systems from transposonsCellDeep-learning-based <em>de novo</em> discovery and design of therapeutics that reverse disease-associated transcriptional phenotypesCellFour centuries of commercial whaling eroded 11,000 years of population stability in bowhead whalesFierceBiotechBeyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndromeAgilentAxion Cleared Of False Advertising Before Agilent Patent Trial - Law360Endpoints NewsLawmakers signal willingness to counter China’s biotech gainsEndpoints NewsSanofi, AbbVie, Novartis and AstraZeneca face revived 340B pricing caseEndpoints NewsFDA opens door to RMAT designations for therapies on clinical holdEndpoints NewsFDA seeks to encourage fewer animal studies with new draft guidanceBioPharma DiveRBC: Revolution, Xenon, Arrowhead among top takeover targets
FierceBiotech Jan 29, 2026

Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials

Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials

Original
Body unavailable. Use the original source.

Directory

59 All